Hyperion DeFi

Operating from the United States, Hyperion DeFi, Inc. is a company undergoing a significant shift from its foundational work in ophthalmic drug-delivery, known as Optejet. Its current trajectory involves establishing itself as the inaugural U.S. firm on Nasdaq to hold a cryptocurrency treasury, predominantly denominated in HYPE tokens originating from the Hyperliquid blockchain. Furthermore, Hyperion DeFi oversees the "Kinetiq × Hyperion" validator, persists with its decentralized finance (DeFi) staking strategies, and continues to advance its Optejet UFD™ technology for ocular health.